Action against Respondent, a pharmaceutical company, in connection with alleged selective disclosures of material nonpublic information regarding a potential FDA drug approval to sell-side research analysts who covered Respondent.  According to the SEC, Respondent sent private messages to analysts describing an FDA meeting as “very positive and productive.”  Respondent has agreed to pay a civil penalty of $200,000.

SEC Order

SEC Press Release